Angiogeneza w złośliwych nowotworach ginekologicznych

• Authors: Anna Markowska , Karolina Jaszczyńska-Nowinka , Joanna Kaysiewicz , Anna Makówka , Janina Markowska

Title variants

EN

Angiogenesis in gynecologic malignancies

• Languages of publication: EN PL

Abstracts

EN

Angiogenesis is crucial for the development and progression of malignant neoplasms. In terms of molecular mechanisms leading to the development of genital malignancies, the development has contributed to improved survival of patients as a result of antiangiogenic therapy, which is targeted against the vascular endothelial growth factor. Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. This article reviews the results of studies using bevacizumab in ovarian cancer, which gave rise to its registration by the European Medicines Agency in 2011 in Poland. In addition, the effects of bevacizumab in recurrent, platinum-resistant ovarian cancer (AURELIA), the drug’s safety profile (ROSIA), other routes of administration (intraperitoneal) as well as an assessment of the efficacy and safety of neoadjuvant bevacizumab (ANTHALYA) were presented. Attention was paid to the location of recurrence after treatment with bevacizumab and escape from antiangiogenic therapy and therapeutic resistance. Bevacizumab combined with chemotherapy in persistent or recurrent cervical cancer improved both – overall survival and time to progression. That has become the baseline for an open-label global safety study (CECILIA) evaluating the efficacy and complications of bevacizumab. The presented study on the use of bevacizumab in the treatment of endometrial cancer shows promising results.

PL

Angiogeneza ma kluczowe znaczenie dla powstawania i progresji nowotworów złośliwych. Postęp w rozumieniu mechanizmów molekularnych prowadzących do rozwoju nowotworów narządu rodnego przyczynił się do poprawy przeżycia chorych dzięki wdrażaniu leczenia antyangiogennego – skierowanego przeciwko naczyniowośródbłonkowemu czynnikowi wzrostu. W artykule dokonano przeglądu wyników badań nad stosowaniem bewacyzumabu w raku jajnika, które dały podstawę do zarejestrowania leku przez European Medicines Agency w 2011 roku. Ponadto przedstawiono efekty przyjmowania bewacyzumabu w nawrotowym platynoopornym raku jajnika (badanie AURELIA), profil bezpieczeństwa leku (ROSIA) oraz inną, dootrzewnową drogę jego podania. Omówiono także badanie ANTHALYA – próbę zastosowania bewacyzumabu w terapii neoadiuwantowej. Zwrócono uwagę zarówno na lokalizację nawrotów po leczeniu bewacyzumabem, jak i na oporność terapeutyczną oraz ucieczkę przed terapią antyangiogenną. Bewacyzumab stosowany w przetrwałym lub nawrotowym raku szyjki macicy wraz z chemioterapią wydłużał nie tylko całkowite przeżycie, lecz także czas do progresji. Dało to podstawę do rozpoczęcia międzynarodowego badania CECILIA, oceniającego efektywność leczenia i powikłania mu towarzyszące. Prezentowane badania nad zastosowaniem bewacyzumabu w leczeniu raka endometrium przynoszą obiecujące wyniki.

Keywords

EN

bevacizumab; bewacyzumab; cervical cancer; endometrial cancer; ovarian cancer; rak endometrium; rak jajnika; rak szyjki macicy

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2015
• Volume: 13
• Issue: 4
• Pages: 256–262

Contributors

author

Anna Markowska

• Department of Perinatology and Women’s Diseases, Poznan University of Medical Sciences, Poznan, Poland. Head of the Department: Professor Krzysztof Drews, MD, PhD

author

Karolina Jaszczyńska-Nowinka

• Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland. Head of the Department: Professor Rodryg Ramlau, MD, PhD

author

Joanna Kaysiewicz

• Roche Poska, Warsaw, Poland

author

Anna Makówka

• Roche Poska, Warsaw, Poland

author

Janina Markowska

• Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland. Head of the Department: Professor Rodryg Ramlau, MD, PhD

References

• 1. D’Andrea LD, Del Gatto A, Pedone C et al.: Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006; 67: 115–126.
• 2. Marech I, Leporini C, Ammendola M et al.: Classical and nonclassical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. Cancer Lett 2015. DOI: 10.1016/j.canlet.2015.07.028.
• 3. Otrock ZK, Makarem JA, Shamseddine AI: Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258–268.
• 4. Burger RA: Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011; 121: 230–238.
• 5. Randall LM, Monk BJ: Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010; 117: 497–504.
• 6. Schmitt J, Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 2012; 38: 272–283.
• 7. Monk BJ, Choi DC, Pugmire G et al.: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005; 96: 902–905.
• 8. Burger RA, Sill MW, Monk BJ et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 5: 5165–5171.
• 9. Cannistra SA, Matulonis UA, Penson RT et al.: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180–5186.
• 10. Burger RA, Brady MF, Bookman MA et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473–2483.
• 11. Perren TJ, Swart AM, Pfisterer JN: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484–2496.
• 12. Kristensen G, Perren T, Qian W et al.: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011; 29 (Suppl), abstr. 5006.
• 13. Aghajanian C, Blank SV, Goff BA et al.: An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. J Clin Oncol 2012; 30 (Suppl 15), abstr. 5054.
• 14. Aghajanian C, Blank SV, Goff BA et al.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039–2045.
• 15. Aghajanian C, Goff B, Nycum LR et al.: Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol Oncol 2014; 133: 105–110.
• 16. Aghajanian C, Goff B, Nycum LR et al.: Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer. Society of Gynecologic Oncology Annual Meeting, 22–25 March: abstr. 137.
• 17. Witteveen P, Lortholary A, Fehm T et al.: Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Eur J Cancer 2013; 49: S3–S4.
• 18. Pujade-Lauraine E, Hilpert F, Weber B et al.: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302–1308.
• 19. Mendiola C, Davidenko I, Colombo N et al.: ROSIA: a single-arm study in more than 1000 patients (pts) receiving front-line bevacizumab (BEV) + chemotherapy (CT) for ovarian cancer (OC). Ann Oncol 2012; 23 (Suppl 9): ix322–ix323.
• 20. Colombo N, Conte PF, Pignata S et al.: Bevacizumab in ovarian cancer: focus on clinical data and future perspectives. Crit Rev Oncol Hematol 2016; 97: 335–348.
• 21. Zhao H, Du N, Fu Y et al.: Clinical study of intraperitoneal injection bevacizumab (BV) combined with intraperitoneal hyperthermic perfusion chemotherapy (CT) in treatment of malignant ascites of ovarian cancer (OC). J Clin Oncol. 2013; 31 (Suppl), abstr. 46F.
• 22. Pujade-Lauraine E: Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer. J Gynecol Oncol 2013; 24: 209–211.
• 23. Vives M, Ginestŕ MM, Gracova K et al.: Metronomic chemotherapy following the maximum tolerated dose is an effective antitumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer 2013; 133: 2464–2472.
• 24. Robinson WR, Beyer J, Griffin S et al.: Extraperitoneal metastases from recurrent ovarian cancer. Int J Gynecol Cancer 2012; 22: 43–46.
• 25. Rauh-Hain JA, Guseh SH, Esselen KM et al.: Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23: 1219–1225.
• 26. Bottsford-Miller JN, Coleman RL, Sood AK: Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012; 30: 4026–4034.
• 27. Selle F, Gouy S, Lambaudie E et al.: Safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: data from the ANTHALYA trial. Eur J Cancer 2015; 51 (Suppl 3): S553.
• 28. Monk BJ, Sill MW, Burger RA et al.: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009; 27: 1069–1074.
• 29. Tewari KS, Sill MW, Long III HJ et al.: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734–743.
• 30. Penson RT, Huang HQ, Wenzel LB et al.: Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015; 16: 301–311.
• 31. Redondo A, Colombo N, McCormack M et al.: CECILIA: an open-label global safety study evaluating bevacizumab, carboplatin and paclitaxel therapy in patients with metastatic, recurrent or persistent cervical cancer. ESGO 2015: abstr. 1078.
• 32. Aghajanian C, Sill MW, Darcy KM et al.: Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29: 2259–2265.

• Document Type: review